Medline ® Abstract for Reference 97
of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.
Tefferi A, Letendre L
Am J Hematol. 2011 Jul;86(7):610-1. Epub 2011 May 31.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. firstname.lastname@example.org